PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

Oxford, UK, 03 March 2021

PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH.

ERA Consulting is a leading strategic product development and regulatory consulting group serving the global biopharmaceutical industry. For nearly 30 years, the company has provided services at all stages of product development, from conception to registration and beyond, and has enjoyed considerable success completing projects on hundreds of products for a wide range of top international clients.

“This transaction highlights our track record in supporting the sale of specialist pharmaceutical clinical services companies in the pharmaceutical industry,” said Dr Fintan Walton, CEO and Founder of PharmaVentures. “Our decades of experience in M&A, together with our detailed knowledge of the pharmaceutical clinical services industry which includes the global regulatory affairs outsourcing market, enabled us to deliver the optimal deal for the owner of ERA Consulting Group.”

Sabine Husmann-Holloway, Co-Founder & CEO of ERA Consulting Group, said, “I feel I made an excellent choice in PharmaVentures to serve as my exclusive advisors for the sale of the Company. They have a comprehensive understanding of our business and helped me identify the ideal partner that shared our strategic vision. The Company’s strong market position was effectively communicated to the potential buyer. I truly value the professional advice and the expert guidance made through every step of the process which enabled us to close the transaction to the satisfaction of all stakeholders.”

Mark Andrews, Managing Director at PharmaVentures said, “In 2020, the global regulatory affairs market was valued at US$ 6.3 billion and is expected to achieve a CAGR of 11.9% over the forecast period between 2021-20281. This particular sector of the Life Sciences market has been experiencing a high degree of consolidation, a trend that is set to continue. This makes it an ideal time for owners of businesses in the pharmaceutical services sector to talk to us about their future plans.”

This M&A deal follows PharmaVentures’ continued success in advising both shareholders in the pharmaceutical services sector on the sale of their businesses as well as major pharmaceutical companies in the divestment of their manufacturing operations to key players in the pharmaceutical services sector.

Source:1 Grand View Research https://www.grandviewresearch.com/industry-analysis/regulatory-affairs-outsourcing-market

– Ends –

For further information, contact:

Lisa Holloway
Senior Marketing Manager
PharmaVentures Ltd
+44 (0) 1865 332 700
enquiries@pharmaventures.com

Distributed by PR Newswire (Cision)

About PharmaVentures

PharmaVentures is a premier transaction advisory firm and a leading international company in partnering, M&A deals and strategic alliances. For the past 28 years, PharmaVentures has acted as advisor on over 900 deal related projects covering licensing, mergers, acquisitions, divestments, and joint venture activities for companies world-wide.

PharmaVentures’ deep bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes it uniquely placed to support business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures’ services include:

• M&A (divestments, mergers, acquisitions, and strategic transactions)
• Licensing (in and out licensing)
• Fundraising
• Strategy (commercialisation, deal strategy, due diligence, market entry)
• Valuation and Positioning (licensing, M&A, and fundraising)

PharmaVentures is based in Oxford, UK, and employs over 20 professionals and has associates in Europe and Asia-Pacific.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356).

For more details, visit www.pharmaventures.com.

PharmaVentures advises GPCR Therapeutics on their acquisition of Burixafor

Oxford, UK, 24th November 2020

PharmaVentures today announced it has acted as an advisor to GPCR Therapeutics, Inc (GPCR) providing due diligence for their acquisition of Burixafor targeting CXCR4.

GPCR has signed an exclusive agreement with TaiGen Biotechnology Company Ltd (TaiGen) for the development of Burixafor for worldwide markets.

GPCR Therapeutics is a leading Korean biotechnology company, a world leader in the field of GPCR heteromer science and has proprietary expertise and technology applicable to the development of this class of anti-cancer targets. CXCR4 antagonism is an accepted avenue for cancer therapy and GPCR Therapeutics has significant experience and knowledge that will enable the development of Burixafor in the oncology field.

Dongseung Seen, CEO of GPCR Therapeutics, said, “This collaboration with TaiGen, which is a leading biotech company engaged in innovative molecular-based platforms with strong R&D capabilities, will lead to a long-term strategic and productive partnership. Further, it is our goal that our work together will position us to be a pre-eminent developer of anti-CXCR4 oncology drugs.”

Summer Park, Senior Business Development Director, PharmaVentures said: “In the past decade we’ve seen more exciting innovative technologies coming out of Korea. We are proud to have supported GPCR in this process which has enabled the company to further its aim of developing novel and effective anti-cancer therapies.”

Adrian Dawkes, Managing Director at PharmaVentures, added “South Korea is forging ahead with the internationalisation of its innovative biotechnology sector and we, at PharmVentures, are pleased to be able to bring our knowledge of both Korean and Western cultures to support our Korean clients with their global transactions.”

This partnering deal follows PharmaVentures’ continued successes in working with Korean companies to enable them to expand further into the international market.

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances.

An unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal-making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.

PharmaVentures Capital Ltd is a wholly owned subsidiary of PharmaVentures Ltd. All regulated activities are delivered through PharmaVentures Capital Ltd, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Ltd undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5.

Services include:

  • Pharma M&A (divestments, pharma mergers, acquisitions and strategic transactions)
  • Strategy (commercialisation, deal strategy, due diligence, market entry)
  • Valuation and Positioning (licensing, M&A, fundraising & expert testimonies)
  • Licensing (in and out licensing)
  • Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
  • Private Placement Fundraising

PharmaVentures is based in Oxford, UK, employs over 20 professionals and has associates in N. America, Latin America, Asia-Pacific.

For further information, contact:

Dr Fintan Walton

CEO

PharmaVentures Ltd

+44 1865 332 700

enquiries@pharmaventures.com

PharmaVentures advises Vital Foods on the sale of its Zyactinase-based digestive health product asset portfolio to Mundipharma.

Oxford, England, 6th September 2018

PharmaVentures Ltd (“PharmaVentures”) is pleased to announce that it acted as exclusive adviser to Vital Food Processors Ltd (“Vital Foods”), an agricultural science company founded in New Zealand, on an asset purchase agreement with Mundipharma for the global rights beyond New Zealand to commercialise Zyactinase™ – a clinically-proven gastrointestinal consumer health product.

Zyactinase™is the basis of market leading, natural, plant-based consumer health products for the promotion of digestive health.  Zyactinase™ is a freeze-dried extract of Kiwifruit (Actinidia deliciosa) that has been developed as a constipation relief product as well as for long-term gut health. It contains a protease complex, fiber, pectin and fructo-oligosaccharides that stimulates increased bowel movements.

Under the agreement, Mundipharma will initially focus on the commercialising of Zyactinase™ to establish a foothold in the US and Canada markets, while continuing to supply existing partners. It will then look to expand its marketing and distribution footprint globally.

This agreement will also enable the extension of the company’s Senokot®product range in the US, which is also an all natural, clinically proven digestive health supplement for the treatment of constipation. (see http://www.prnewswire.co.uk/news-releases/mundipharma-closes-acquisition-of-vital-food-processors-limited-assets-and-secures-global-rights-to-692559241.html)

Adrian Dawkes, Managing Director, who led the deal at PharmaVentures, commented; “The consumer health space has seen significant deal activity recently and, not surprisingly, there was a lot of interest in Vital Foods’ assets. We are delighted to have been able to secure this deal with Mundipharma who are ideally placed to maximise the potential of Zyactinase”.

Fintan Walton, Founder and Chief Executive of PharmaVentures said; “We are particularly pleased to have brought PharmaVentures’ broad experience and skills to bear in another cross-border deal where the pairing of high-quality assets from Vital Foods with an ideal acquirer in Mundipharma has resulted in an excellent outcome for all”.

  

PharmaVentures advises SalvaRx Group plc on the acquisition of SalvaRx Ltd by Portage Biotech Inc.

Oxford, UK, 20 August 2018

PharmaVentures Ltd. (“PharmaVentures”) is pleased to announce that it acted as an independent adviser to SalvaRx Group plc (SALV:LSE) (“SalvaRx”) and Portage Biotech, Inc (“Portage”), on the acquisition of its subsidiary SalvaRx Ltd by Portage. Subject to regulatory and shareholder consent, Portage will acquire 100% of SalvaRx Limited for an aggregate consideration of US$71.7 Million. 

SalvaRx is a related party of Portage, the transaction is subject to the requirements of Alberta Securities Commission’s Multilateral Instrument 61-101 Protection of Minority Shareholders in Special Transactions (“MI 61-101”). As a consequence, the Transaction requires minority shareholder approval.

Although the transaction is exempt from the formal valuation requirements of MI 61-101 pursuant to Section 5.5(a) PharmaVentures was commissioned by SalvaRx and Portage to perform an independent valuation (the “Valuation”) of SalvaRx Limited. The Valuation, dated July 23, 2018, provided the parties with, amongst other things, a discussion of various methodologies to value SalvaRx Limited as well as a range of possible values.

For more information see the Portage Biotech press release: https://www.prnewswire.com/news-releases/portage-to-acquire-salvarx-limited-300696910.html.

Adrian Dawkes, Managing Director, PharmaVentures, commented; “We have worked previously with SalvaRx and were pleased to provide our extensive valuation capabilities and market knowledge to assist in this transaction”.

Fintan Walton, Founder and Chief Executive of PharmaVentures said; “PharmaVentures is trusted by long established pharmaceutical companies, governments as well as innovative biotechs like SalvaRx to provide high quality, robust and comprehensively researched valuations to support their key strategic transactions. We are pleased to have assisted SalvaRx in their endeavors”. 

PharmaVentures Strengthens Its First-Class Strategy Consulting & Dealmaking Capabilities

PharmaVentures strengthens its first class healthcare strategy and dealmaking capabilities with the recruitment of a new Vice President, Ashley Cox.

Ashley has built significant industry experience working directly for a number of pharmaceutical companies, undertaking both Project Execution and Business Development activities.  Most notably, she has worked for firms such as Lundbeck, Teva and Glenmark, where she led business development and sales activities across a wide range of products and services.

Fintan Walton, PhD, Chief Executive of PharmaVentures, said: “We are delighted to welcome Ashley to PharmaVentures. She has an impressive track record in healthcare strategy consulting and dealmaking. Her wealth of experience will add significant value to our clients in their dealmaking and commercial strategy activities”.

 

Most recently, Ashley worked with SmartAnalyst, Inc., as the Senior Director, European Business Development supporting Global Pharmaceutical and Biotech clients in their disease, asset and portfolio strategy development. Previously, Ashley was Head of Global Business Development for the Prescient Healthcare Group, with a strong focus on Competitive Intelligence and Business Analytics.  Ashley has supported decision making in the majority of the top 20 pharma companies and many biotech companies. She started her career as a Medical Representative and has held a variety of commercial and licensing roles across the pharmaceutical and generics sectors.

Ashley received a BSc. (Hons). in Neuroscience from the University of Glasgow and a Masters in Pharmaceutical Analysis from the University of Strathclyde.